Intravenous Thrombolysis in Acute Myocardial Infarction Ohman E. Magnus , MD, FCCP, Harrington Robert A. , MD, Cannon Christopher P. , MD, Agnelli Giancarlo , MD, Cairns John A. , MD, Kennedy J.Ward , MD CHEST Volume 119, Issue 1, Pages 253S-277S (January 2001) DOI: 10.1378/chest.119.1_suppl.253S Copyright © 2001 The American College of Chest Physicians Terms and Conditions
Figure 1 Structure of t-PA and mutant forms. Reprinted from Brener and Topol15 with permission. CHEST 2001 119, 253S-277SDOI: (10.1378/chest.119.1_suppl.253S) Copyright © 2001 The American College of Chest Physicians Terms and Conditions
Figure 2 Patency rates (TIMI grade 2 or 3 flow) in patientstreated with streptokinase, accelerated alteplase, standard-dosealteplase, or anistreplase for acute MI, vs control subjects. Adaptedfrom Granger et al,42 with permission. CHEST 2001 119, 253S-277SDOI: (10.1378/chest.119.1_suppl.253S) Copyright © 2001 The American College of Chest Physicians Terms and Conditions
Figure 3 Incidence of TIMI grade 2 or 3 flow 90 min afterTNK-tPA or accelerated alteplase treatment in the TIMI-10B trial.Reprinted from Cannon et al,22 with permission. CHEST 2001 119, 253S-277SDOI: (10.1378/chest.119.1_suppl.253S) Copyright © 2001 The American College of Chest Physicians Terms and Conditions
Figure 4 Dosing schedule of weight-adjusted TNK-tPA used inthe ASSENT-2 trial. Reprinted with permission fromLancet.127 CHEST 2001 119, 253S-277SDOI: (10.1378/chest.119.1_suppl.253S) Copyright © 2001 The American College of Chest Physicians Terms and Conditions